Kronos Bio, Inc. Deferred Tax Assets, Valuation Allowance
Kronos Bio, Inc. had Deferred Tax Assets, Valuation Allowance of $141.44 million as of 2024-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2025-03-18
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $141.44M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $122.97M.
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $100.66M.
- 2021-12-31: Deferred Tax Assets, Valuation Allowance $58.71M.
| Period end | Deferred Tax Assets, Valuation Allowance |
|---|---|
| 2024-12-31 | $141.44M 10-K · filed 2025-03-18 |
| 2023-12-31 | $122.97M 10-K · filed 2025-03-18 |
| 2022-12-31 | $100.66M 10-K · filed 2024-03-21 |
| 2021-12-31 | $58.71M 10-K · filed 2024-03-21 |
| 2020-12-31 | $20.80M 10-K · filed 2023-03-15 |
| 2019-12-31 | $5.74M 10-K · filed 2021-03-23 |